BLOG
Innovatiemakelaars op missie

Maandelijks geeft een innovatiemakelaar van ChemistryNL je inzicht in zijn/haar dagelijkse werk. Lees de blogs van Martin van Dord, Caroli Buitenhuis, René Reijtenbagh, Eric van Sprang, Marco Tibaldi en Lays da Cruz.

Deze maand: Lays da Cruz

Blog: The Hidden Barrier in Health Innovation: Why only collaboration can bridge the gap between molecules and impact

Science does not exist in isolation. Its success depends on how well research, policy, and real-world implementation connect. My background in molecular biology includes experience with early-stage drug discovery and diagnostics, and what truly engaged me was not just the science itself but the opportunity to transform research into meaningful solutions. Whether in therapeutic development, diagnostics, or broader life sciences and health innovation, the challenge lies in bridging the gap between the molecules and impact.

Working in the Netherlands has shown me how the country’s strong infrastructure and collaborative culture among academia, industry, and government create an ideal environment for advancing life sciences and health. Yet, even in such a supportive setting, many promising innovations fail to progress beyond early stages. The issue is rarely the science. More often, it is the lack of hands-on support during critical early phases.

A recent project I was involved in illustrates this well. A brilliant principal investigator was developing a groundbreaking sensing technology capable of surpassing current gold standards in early detection of a cancer type with a 60 percent mortality rate. However, the real challenge lies far before scaling up this solution; it stands between development and validation. Defining a product classification, the intended use definition, and understanding how a product is viewed from a regulatory perspective are tasks that often fall outside the typical scope of academic work. Only multidisciplinary collaboration can address these challenges effectively. Overlooking the need for a specialized assessment, either during paperwork or early-stage bench work, can jeopardize the entire development of such a promising innovation.

While the Netherlands’ competitiveness in life sciences and health depends heavily on small and medium-sized enterprises, this area remains fragile. Strengthening it requires consistent funding, continuously improved infrastructure, and embedded policy support for research and development. The greatest challenges in health innovation, whether in therapeutic development or diagnostic access, are not purely scientific. They demand aligned incentives, shared risks, and a commitment to equity.

Coordination, strategic resource sharing, governance, and acceptance in the ecosystem present far greater hurdles when ensuring the successful development of novel LS&H technologies. The most transformative innovations do not come from a single hospital, biotech company, or technology provider. They emerge when hospitals, biotech firms, pharmaceutical companies, regulators, funders, and innovators collaborate.

The pharma and life sciences sector continues to grow despite a cautious investment climate. Smaller transactions and alternative collaboration models are becoming more common, with biotech remaining particularly attractive for mid-sized companies. Large pharmaceutical firms are increasingly pursuing mergers and acquisitions, joint ventures, and partnerships. Supply chain disruptions, tariffs, and policies that often discourage local drug manufacturing are also influencing Dutch companies. To maintain competitiveness, the ecosystem must adapt quickly.

Looking ahead, we should focus on several key areas. Cross-sector collaboration that bridges science, policy, care, industry, and regulation will be essential. Implementation must receive as much attention as innovation itself. Innovation should be human-centred, not just technology-driven. Finally, the Dutch government’s incentives and subsidies for research, development, and innovation are valuable. Their full potential can only be realized when these schemes work together rather than in isolation.

The future of health innovation depends not only on scientific breakthroughs but also on how well we connect, coordinate, and collaborate. That is where the real work and the greatest opportunities lie. Let’s keep the conversation going. Connect with me on LinkedIn to share your thoughts or explore collaborations.

Meer informatie over onze innovatiemakelaars:
Gratis deskundige support om te versnellen
Wie zijn onze innovatiemakelaars?